Skip to Content
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees
  • Market Value — as of March 31, 2016 ($M)
  • Previous Rank
  • Morning Consult Brand Index

Pfizer will have to find a way to boost profits that doesn’t entail cutting its tax bill. In early 2016, the U.S. Treasury Department scuttled its planned inversion with Ireland-based Allergan, which would have moved the Big Pharma company’s headquarters overseas. The New York-based drug maker, which benefited from its blockbuster medication Lipitor before it went off patent, was hoping to reduce its tax rate through the $150 billion deal, which would have been the largest pharmaceutical merger in history. Instead, Pfizer will have to focus on reviving its core business, which has been in decline. The company’s sales dropped 1.5% in 2015 as it still deals with the impact of patent expirations on some of its biggest drugs. Its profits, meanwhile, fell nearly 24%, largely due to a surge in acquisition-related costs, which more than quintupled from the previous year due to Pfizer’s purchase of Hospira in early 2015. Pfizer’s stock fell 14.2% in 2015, a result of its performance as well as concerns that drug price regulation could hamper its profitability.

Company Info

Acquired Hospira (2014 rank: 575), Sept. 3, 2015.
Ian C. Read
Health Care
HQ Location
New York, NY
Years on Fortune 500 List22

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$48,851-1.5%
Profits ($M)$6,960-23.8%
Assets ($M)$167,460-
Total Stockholder Equity ($M)$64,720-
Market Value — as of March 31, 2016 ($M)$183,298-

Profit Ratios

Profit as % of Revenues14.2%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity10.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.11
EPS % Change (from 2014)-21.8%
EPS % Change (5 year annual rate)1.7%
EPS % Change (10 year annual rate)0.2%

Total Return

Total Return to Investors (2015)7.1%
Total Return to Investors (5 year, annualized)17.1%
Total Return to Investors (10 year, annualized)7.8%